726 results on '"Carella, A. M."'
Search Results
2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
3. Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian 'Back to Life' project
4. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
5. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
6. Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti
7. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors
8. Structural insight into halide-coordinated [Fe4S4XnY4−n]2− clusters (X, Y = Cl, Br, I) by XRD and Mössbauer spectroscopy
9. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
10. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
11. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
12. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support
13. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
14. P1084: CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN’S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP).
15. Combined Use of Auto-Grafting and Non-Myeloablative Allografting for the Treatment of Hematologic Malignancies and Metastatic Breast Cancer
16. Autograft Followed by Allograft Without Myeloablative Conditioning Regimen: A New Approach for Resistant Hematologic Neoplasia and Breast Cancer
17. Structural insight into halide-coordinated [Fe4S4XnY4−n]2− clusters (X, Y = Cl, Br, I) by XRD and Mössbauer spectroscopy.
18. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
19. Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)
20. Philadelphia (Ph)-Chromosome-Negative Peripheral Blood Stem Cells can be Mobilized in the Early Phase of Recovery after a Myelosuppressive Chemotherapy in Ph-Chromosome-Positive Acute Lymphoblastic Leukemia
21. Conditioning Regimens for Bone Marrow and Peripheral Blood Stem Cell Transplantation
22. Effective thermal conductivity of functionally graded random micro-heterogeneous materials using representative volume element and BEM
23. Meet the Editorial Board Member
24. Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia
25. Allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory multiple myeloma: possible cures and acceptable toxicities: AB97
26. Total body irradiation (TBI)-based versus chemotherapybased myeloablative conditioning regimen before allogeneic stem cell transplantation (allo-sct) for acute myeloid leukemia (AML). A single centre experience: AB59
27. Haploidentical stem cell transplantation followed by highdose cyclophosphamide post transplant as GVHD prophylaxis in high-risk haematologic malignancies: a retrospective multicentric experience from the REP (Rete Ematologica Pugliese): AB24
28. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen
29. Brain Natriuretic Peptide: Itʼs Not About the Brain or Just Another Smart Polypeptide—Itʼs About the Heart
30. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
31. Therapy of Acute-Phase Chronic Myelogenous Leukemia with Intensive Chemotherapy, Blood Cell Autotransplantation and Cyclosporine A
32. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
33. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability
34. Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission : Report of the Non-Hodgkin’s Lymphoma Cooperative Study Group (NHLCSG)
35. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes
36. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi
37. Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients
38. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study
39. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
40. BU/melphalan and auto-SCT in AML patients in first CR: a ‘Gruppo Italiano Trapianto di Midollo Osseo (GITMO)’ retrospective study
41. HIGH-DOSE RITUXIMAB IN THE CONDITIONING REGIMEN BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED B-CELL LYMPHOMAS IS ASSOCIATED WITH REDUCED GVHD-RELATED DEATHS, BUT DID NOT IMPROVE DISEASE CONTROL: PH-P393
42. Safety and efficacy of 90Yttrium-Ibritumomab-Tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study
43. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)
44. Adhesion control for injection overmolding of polypropylene with elastomeric ethylene copolymers
45. Macromol. React. Eng. 1/2021
46. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD)
47. Reactor and Product Optimization via Raman Fiber Optics Monitoring: Application to Polymer‐Based Proppants
48. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi
49. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
50. Lenalidomide as salvage therapy in a case of relapse after allogeneic HSCT in a patient with myelodysplatic syndrome with isolated 5q deletion (5q-): R1541
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.